CD32-B/FcγRIIb inhibitors are a class of chemical compounds designed to specifically target and inhibit the function of CD32-B, also known as Fc gamma receptor IIB (FcγRIIb), a low-affinity receptor for the Fc region of immunoglobulin G (IgG). CD32-B is unique among the Fcγ receptors because it possesses an immunoreceptor tyrosine-based inhibition motif (ITIM) in its cytoplasmic tail, which confers inhibitory signaling capabilities. This receptor is primarily expressed on the surface of B cells, monocytes, macrophages, and dendritic cells, and it plays a crucial role in downregulating immune responses by dampening the activation of these cells. Upon binding to immune complexes (antigen-antibody complexes), CD32-B recruits phosphatases that dephosphorylate key signaling molecules, thereby inhibiting activation pathways that would otherwise lead to immune cell activation, proliferation, and cytokine production. By inhibiting CD32-B, researchers can disrupt these negative feedback mechanisms, allowing for the study of immune regulation and signaling.
In research settings, CD32-B/FcγRIIb inhibitors are valuable tools for exploring the complex regulatory networks that balance immune activation and suppression. By blocking CD32-B activity, scientists can investigate how the inhibition of this receptor affects the activation thresholds of B cells and other immune cells, thereby providing insights into the mechanisms that maintain immune homeostasis. This can lead to a better understanding of the role of CD32-B in modulating immune responses, particularly in contexts where overactivation or insufficient activation of immune cells can have significant consequences. Additionally, CD32-B inhibitors allow researchers to study the interactions between CD32-B and other Fcγ receptors, elucidating the balance between activating and inhibitory signals that control immune cell function. Through these studies, the use of CD32-B/FcγRIIb inhibitors contributes to a deeper understanding of immune regulation, the role of Fcγ receptors in immune complex handling, and the intricate signaling pathways that ensure appropriate immune responses to various stimuli.
SEE ALSO...
Items 1 to 10 of 12 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
BAY 11-7082 | 19542-67-7 | sc-200615B sc-200615 sc-200615A | 5 mg 10 mg 50 mg | $62.00 $85.00 $356.00 | 155 | |
BAY 11-7082 inhibits NF-κB activation by blocking IκBα phosphorylation, which can decrease the expression of FCGR2B due to NF-κB’s role in its transcriptional regulation. | ||||||
LY 294002 | 154447-36-6 | sc-201426 sc-201426A | 5 mg 25 mg | $123.00 $400.00 | 148 | |
LY294002 is a PI3K inhibitor that prevents phosphorylation of AKT, potentially reducing FCGR2B-mediated signaling which can be PI3K/AKT pathway dependent. | ||||||
Wortmannin | 19545-26-7 | sc-3505 sc-3505A sc-3505B | 1 mg 5 mg 20 mg | $67.00 $223.00 $425.00 | 97 | |
Wortmannin is another PI3K inhibitor that can attenuate downstream signaling cascades such as AKT, potentially modulating the activity of FCGR2B. | ||||||
Cyclosporin A | 59865-13-3 | sc-3503 sc-3503-CW sc-3503A sc-3503B sc-3503C sc-3503D | 100 mg 100 mg 500 mg 10 g 25 g 100 g | $63.00 $92.00 $250.00 $485.00 $1035.00 $2141.00 | 69 | |
Cyclosporin A inhibits calcineurin, thereby affecting NFAT (nuclear factor of activated T-cells) which indirectly influences the expression of FCGR2B. | ||||||
Monensin A | 17090-79-8 | sc-362032 sc-362032A | 5 mg 25 mg | $155.00 $525.00 | ||
Monensin A is an ionophore that disrupts lysosomal pH, potentially affecting the recycling and expression of FCGR2B on the cell surface. | ||||||
Brefeldin A | 20350-15-6 | sc-200861C sc-200861 sc-200861A sc-200861B | 1 mg 5 mg 25 mg 100 mg | $31.00 $53.00 $124.00 $374.00 | 25 | |
Brefeldin A disrupts Golgi apparatus function, which can lead to mislocalization of FCGR2B, impairing its surface expression and function. | ||||||
Stat3 inhibitor V, stattic | 19983-44-9 | sc-202818 sc-202818A sc-202818B sc-202818C sc-202818D sc-202818E sc-202818F | 25 mg 100 mg 250 mg 500 mg 1 g 2.5 g 5 g | $130.00 $196.00 $274.00 $512.00 $731.00 $1408.00 $2091.00 | 114 | |
Stattic selectively inhibits STAT3, which can downregulate the expression of FCGR2B by interfering with STAT3-mediated signaling pathways. | ||||||
Dasatinib | 302962-49-8 | sc-358114 sc-358114A | 25 mg 1 g | $70.00 $145.00 | 51 | |
Dasatinib is a Src family kinase inhibitor that may reduce FCGR2B signaling through its inhibition of Fc receptor-mediated phosphorylation pathways. | ||||||
PP 2 | 172889-27-9 | sc-202769 sc-202769A | 1 mg 5 mg | $94.00 $227.00 | 30 | |
PP2 is an inhibitor of Src family kinases which are involved in FCGR2B signaling; inhibition could reduce FCGR2B-mediated immune responses. | ||||||
SU6656 | 330161-87-0 | sc-203286 sc-203286A | 1 mg 5 mg | $57.00 $133.00 | 27 | |
SU6656 is another Src family kinase inhibitor, potentially decreasing FCGR2B-mediated activities by blocking Src-related pathways. | ||||||